https://www.mdpi.com/1010-660X/57/3/225/htm
Worth a readMatriDerm®, a dermal, cell-free skin substitute for deep-seated burns, has been commercially available for several years. The matrix consists of bovine collagen type I, collagen type III and elastin. As studied in animal models, MatriDerm® matrix is converted into endogenous matrix by the recipient organism over a period of weeks [71,77]. Similar biodegradable behavior has also been demonstrated in the human organism [78]. MatriDerm® is available in various thicknesses and can be stored at room temperature, making handling considerably easier than with other biomaterials [71]. In particular, the single-stage procedure with simultaneous autologous split-thickness skin grafting is clinically considered a significant advantage and showed no inferiority to allogeneic split-thickness skin grafting alone [3]. Better scar quality as well as reduced wound contraction were observed [79,80], so the results to date in clinical application are promising [80,81]. However, full-thickness skin replacement with MatriDerm® is so far only possible in combination with autologous split-thickness skin grafting.NovoSorb® BTM is a fully synthetic dermal skin substitute that eliminates any risks of cross-species residual antigenicity. It consists of biodegradable polyurethane foam with a temporary non-biodegradable polyurethane seal. Thereby, it is easy and inexpensive to produce [76]. A further advantage is the avoidance of cross-species immune rejection or disease transmission as well as circumventing ethical and cultural objections to the use of animal derived products. A plethora of proof-of-concept studies using NovoSorb® BTM has been conducted to determine its safety and ability to provide permanent wound closure when combined with split-thickness skin grafts in a two-stage procedure in sheep, pigs and humans [82,83]. Furthermore, the particular abundance of host inflammatory cells in athymic nude mice receiving full-thickness skin excision followed by grafting of the dermal NovoSorb® BTM template, showed evidence that new collagen deposition and neovascularization with BTM had a more extensive vascular network compared to Integra® (Integra LifeSciences, Plainsboro, NJ, USA) [84]. NovoSorb® BTM demonstrates favorable properties as dermal skin substitute but further studies are needed to evaluate its position in clinical routine, especially for the treatment of burns.
- Forums
- ASX - By Stock
- PNV Media Thread
https://www.mdpi.com/1010-660X/57/3/225/htmWorth a...
-
- There are more pages in this discussion • 2,031 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PNV (ASX) to my watchlist
|
|||||
Last
$2.52 |
Change
-0.050(1.95%) |
Mkt cap ! $1.739B |
Open | High | Low | Value | Volume |
$2.60 | $2.60 | $2.51 | $2.348M | 921.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 22274 | $2.51 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.53 | 10711 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 22274 | 2.510 |
8 | 37588 | 2.500 |
2 | 8885 | 2.490 |
2 | 2689 | 2.480 |
1 | 2189 | 2.470 |
Price($) | Vol. | No. |
---|---|---|
2.530 | 10711 | 1 |
2.550 | 32424 | 4 |
2.560 | 11385 | 3 |
2.570 | 2189 | 1 |
2.580 | 27189 | 2 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online